WHO ICTRP trial
Safety and tolerability of the Japanese encephalitis vaccine IC51 (JE-PIV)…
EUCTR2005-000100-14-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2005-000100-14-DE |
|---|---|
| Public title | Safety and tolerability of the Japanese encephalitis vaccine IC51 (JE-PIV). Double blind, randomized, placebo controlled phase 3 study - IC51- 302 |
| Scientific title | Safety and tolerability of the Japanese encephalitis vaccine IC51 (JE-PIV). Double blind, randomized, placebo controlled phase 3 study - IC51- 302 |
| Primary sponsor | Intercell AG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | United Kingdom;Germany |
| Conditions | Japanese encephalitis (JE) is the most common viral encephalitis, with over 50,000 cases reported annually. It is a considerable public health problem for many Asian countries (WHO 1997). Close to 3 billion people now live in regions at… |
| Interventions | Product Name: Japanese Encephalitis Purified Inactivated Vaccine Product Code: IC51 (JE-PIV) Pharmaceutical Form: Suspension for injection Current Sponsor code: IC51 Other descriptive name: Japanese Encephalitis-Purified Inactivated Vaccine… |
| Registration date | Jan 25, 2005 |
| Target size | 2680 |
| Secondary IDs | IC51- 302 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: